Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Bone Therapeutics
Bone Therapeutics
Activities:
Regulatory
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Regulatory
Bone Therapeutics enters reverse merger discussions with Medsenic
Bone Therapeutics would remain a Belgian listed company and own 51% of the share capital of Medsenic
Research & Development
Bone Therapeutics refocuses on lead clinical asset
A number of actions have been taken to reduce the company’s cost base and enable completion of a Phase IIb study on ALLOB
Finance
Catalent to acquire facility from Bone Therapeutics
In addition to the expansion in Gosselies, validation of Catalent’s new 32,000 sqft cell therapy development facility in Houston, Texas is underway
Pharmaceutical
Bone Therapeutics invests in cell therapy manufacturing facility
New Belgian plant should be fully operational by 2015
Subscribe now